Form 4: Sage Therapeutics Director Disposes of Shares and Options Following Merger Completion

A director of Sage Therapeutics, Inc. disposed of common stock and stock options as part of the company's merger with a Supernus Pharmaceuticals subsidiary, receiving cash and contingent value rights.

Summary

• Elizabeth A. Barrett, a Director of Sage Therapeutics, Inc., disposed of 3,000 shares of common stock and 21,500 stock options on July 31, 2025.
• This disposition occurred as a direct result of the merger between Sage Therapeutics, Inc. and Saphire, Inc., a wholly-owned subsidiary of Supernus Pharmaceuticals, Inc., which became effective on July 31, 2025.
• Each outstanding common share was converted into $8.50 in cash plus one contingent value right (CVR), which can yield up to an additional $3.50 per share based on specified milestones.
• Stock options with an exercise price less than the $8.50 closing amount were fully vested, cancelled, and converted into a cash payment equal to the difference between the closing amount and the exercise price, multiplied by the number of shares, plus one CVR per option.
• For the 21,500 options with an exercise price of $6.77, the cash payment amounted to $37,195, in addition to 21,500 CVRs.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger, which provides a defined cash value and potential upside via CVRs for shareholders and option holders. This represents a clear exit strategy and monetization event for the company's equity, generally a positive outcome for investors who held shares prior to the merger announcement.

Positives

• The merger provides immediate cash value of $8.50 per share to shareholders and option holders.
• Contingent Value Rights (CVRs) offer potential additional upside of up to $3.50 per share upon achievement of specified milestones.
• Stock options with an exercise price below the merger's closing amount were fully vested and converted into cash and CVRs, providing value to option holders.

Negatives

• Existing shareholders no longer hold equity in Sage Therapeutics, Inc. as it has merged into a subsidiary.
• The future value of the CVRs is contingent and not guaranteed, depending on the satisfaction of specific milestones.
• Stock options with an exercise price greater than or equal to the closing amount were cancelled without any consideration.

Risks

• The value of the Contingent Value Rights (CVRs) is subject to the achievement of specified milestones, meaning the full $3.50 per share is not guaranteed.

Future Outlook

The filing indicates that contingent value rights (CVRs) offer potential future payments of up to $3.50 per share, contingent upon the satisfaction of specified milestones.

Industry Context

This filing reflects a consolidation event within the biotechnology or pharmaceutical industry, where a larger entity (Supernus Pharmaceuticals) acquires a smaller one (Sage Therapeutics). Such mergers are common strategies for companies to expand their product pipelines, market share, or intellectual property.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in M&A transactions is a common mechanism in the pharmaceutical and biotechnology sectors, particularly when the acquired company has pipeline assets whose future value is uncertain or dependent on regulatory approvals or commercial milestones.
• Examples include the acquisition of Spark Therapeutics by Roche, where CVRs were tied to the approval of Luxturna, or the acquisition of MyoKardia by Bristol Myers Squibb, which also included CVRs.
• The specific cash component of $8.50 per share and potential additional $3.50 via CVRs would need to be compared against recent M&A valuations for similar-stage biotech companies, considering Sage's specific drug pipeline and market position prior to the merger. Without more context on Sage's pre-merger valuation and pipeline, a direct comparison to specific companies or projects is not feasible from this Form 4 alone.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, effectively exiting their investment in Sage Therapeutics as a standalone entity.
• Employees (with options): Those with in-the-money options received cash and CVRs, monetizing their equity compensation.
• Company (Sage Therapeutics): Ceased to be an independent publicly traded entity, becoming a subsidiary of Supernus Pharmaceuticals.

Next Steps

• Future payments related to the Contingent Value Rights (CVRs) will be made upon the satisfaction of specified milestones.

Key Dates

Recommendation

The company has been acquired, and its shares have been converted into cash and CVRs. There is no longer a publicly traded stock for Sage Therapeutics, Inc. to buy or sell. The 'hold' recommendation applies to the CVRs, as their value is contingent on future milestones. Investors who held Sage shares would have already received the cash portion and now hold CVRs, which they would hold pending milestone achievement.

Keywords

Sage Therapeutics, Supernus Pharmaceuticals, Merger, Acquisition, Form 4, Insider Transaction, Contingent Value Rights, CVR, Stock Options, Equity Compensation, Biotechnology, Pharmaceuticals